• Clear Filters

138 Results |

Immunogenicity, safety, and tolerability of V114, a 15-valent pneumococcal conjugate vaccine, in immunocompetent adults aged 18-49 years with or without risk factors for pneumococcal disease: a randomized phase 3 trial (PNEU-DAY)

Publication date: 12/31/2021

Authors: Hammitt LL, Quinn D, Janczewska E, Pasquel FJ, Tytus R, Rajender Reddy K, Abarca K, Khaertynova IM, Dagan R, McCauley J, Cheon K, Pedley A, Sterling T, Tamms G, Musey L, Buchwald UK

Publication: Open Forum Infectious Diseases

Focus Area: Infectious Disease Prevention